Leadership Team

Steven Fischkoff, M.D.

Steven Fischkoff, M.D.

Interim Chief Medical Officer

Dr. Steven Fischkoff serves as the interim Chief Medical Officer of Adagene. Dr. Fischkoff is a Board Certified Medical Oncologist who has been active in the pharmaceutical industry for 29 years. He has proven track record and leadership in developing some of the most innovative therapeutics with responsibility in a broad range of clinical, management, and regulatory activities.

At Medarex, Dr. Fischkoff was responsible for the clinical development of ipilimumab (Yervoy) leading to its US FDA approval in 2011. He led the team who completed the Phase 2 trial of ipilimumab, and designed the Phase 3 trial which demonstrated a significant survival advantage in metastatic melanoma. Ipilimumab was the first ever immune checkpoint inhibitor approved by the FDA and remains the only FDA-approved anti-CTLA-4 product up to date.

At Knoll Pharmaceutics and through the acquisition by Abbott, Dr. Fischkoff served as the clinical lead for the development of adalimumab (Humira®), taking it from first-in-man through submission and approval in the US and the EU. In addition, while at Knoll, he ran clinical trials for a monoclonal antibody to treat sepsis and a number of small molecule oncology compounds. At Lederle Laboratories, he contributed to the development of levoleucovorin (Isovorin®) for colorectal cancer and mitoxantrone for breast and prostatic cancer.

At Palatin Biotechnologies, Dr. Fischkoff led the clinical development of bremelanotide (Vyleesi®) for male and female sexual dysfunction as well as a small molecule compound for heart failure. He spent 8 years at the cell therapy companies Celgene Cellular Therapeutics, Iovance Biotherapeutics (formerly Lion), and WindMIL, pursuing a number of oncology and inflammatory indications including acute myeloid leukemia, Crohn’s disease, multiple sclerosis, stroke, lung cancer, melanoma, and sarcoidosis. At Sun Pharma Advanced Research Company, he worked on studies and submissions for a variety of small molecules to treat Parkinson’s disease, chronic myelogenous leukemia, prostate cancer, and skin cancer.

Prior to joining the industry, Dr. Fischkoff spent 15 years in academic positions at the National Cancer Institute and the medical schools of the University of Maryland and the University of Pennsylvania. He holds an MD from the University of Pennsylvania and oncology training at the NCI-Baltimore Cancer Research Center.

Back to Leadership Team